Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

Chijioke Bennett, E Joy Rivers, Wayne Woo, Mark Bloch, King Cheung, Paul Griffin, Rahul Mohan, Sachin Deshmukh, Mark Arya, Oscar Cumming, A. Munro Neville, Toni McCallum Pardey, Joyce S Plested, Shane Cloney-Clark, Mingzhu Zhu, Raj Kalkeri, Nita Patel, Agi Buchanan, Alex Marcheschi, Jennifer Swan, Gale Smith, Iksung Cho, Gregory M. Glenn, Robert Walker, Raburn M. Mallory the Novavax Inc. 2019nCoV-311 Study Group
doi: https://doi.org/10.1101/2023.07.05.23291954

Article usage

Article usage: July 2023 to February 2025

AbstractFullPdf
Jul 202354417173
Aug 20231182149
Sep 202362613
Oct 202386631
Nov 202394523
Dec 20234019
Jan 202426411
Feb 202424018
Mar 20243306
Apr 202422411
May 20242126
Jun 202422712
Jul 202421518
Aug 20241138
Sep 20242276
Oct 2024331710
Nov 202422520
Dec 2024826
Jan 20251933
Feb 2025741
Back to top
Posted July 06, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial
Chijioke Bennett, E Joy Rivers, Wayne Woo, Mark Bloch, King Cheung, Paul Griffin, Rahul Mohan, Sachin Deshmukh, Mark Arya, Oscar Cumming, A. Munro Neville, Toni McCallum Pardey, Joyce S Plested, Shane Cloney-Clark, Mingzhu Zhu, Raj Kalkeri, Nita Patel, Agi Buchanan, Alex Marcheschi, Jennifer Swan, Gale Smith, Iksung Cho, Gregory M. Glenn, Robert Walker, Raburn M. Mallory
medRxiv 2023.07.05.23291954; doi: https://doi.org/10.1101/2023.07.05.23291954
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area